Martin Dahl, PhD, of AnaptysBio discusses the findings and limitations of a study analyzing use of ANB032 in patients with atopic dermatitis (AD). Lawrence Eichenfield, MD, chief of pediatric and ...

AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price reduced by research analysts at JPMorgan Chase & Co. from $66 ...

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock, ...

AnaptysBio ANAB has been analyzed by 9 analysts ... for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate ...

Note that ANB032 is already no longer part of that pipeline. Until recently it was, and it was being tried in atopic dermatitis. I will address that right away. On December 11, 2024, AnaptysBio ...

The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock ...

On Thursday, Guggenheim adjusted its outlook on shares of AnaptysBio (NASDAQ: NASDAQ:ANAB), reducing the stock's price target to $36 from $90, while keeping a Buy rating. The adjustment follows the ...